Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Manchester University

- PMLiVE

Interlace realigns business to focus on communications

Sells off regulatory and pharmacovigilance interests

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

- PMLiVE

Isis drops arthritis candidate

ISIS-CRP Rx disappoints in phase II

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

- PMLiVE

FDA approves intravenous Simponi for arthritis treatment

J&J says Simponi Aria will offer less frequent dosing schedule than subcutaneous version

- PMLiVE

Pfizer wins Xeljanz approvals in five more countries

Switzerland, Argentina, Kuwait, United Arab Emirates and Russia to receive arthritis drug

- PMLiVE

Mike Birtwistle and Sarah Winstone to leave MHP Health Mandate

Rupert Gowrley and Rachel Rowson will take over as interim heads

Kantar Media and Pointlogic unveil comms planning platform

Will determine most appropriate channel for reaching target audiences

- PMLiVE

AbbVie: UK patients want better arthritis care

Study from Humira manufacturer concludes that UK doctors need better collaboration with patients

- PMLiVE

Novartis launches European advanced breast cancer campaign

Campaign launches with audio/visual installation

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

- PMLiVE

BMS’ Orencia matches Humira in arthritis study

Data should help drug establish itself against AbbVie's market-leading RA medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links